Announcements
Projects
Orgs
Project
Articles 16
Votes 0
Merck.com
Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results - Merck.com
~2mo
U.S. FDA Approves Updated Indication for WINREVAIR™ (sotatercept-csrk) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Based on Phase 3 ZENITH Study - Merck.com
~2mo
Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer - Merck.com
4mo
U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season - Merck.com
6mo
Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia - Merck.com
6mo
Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline - Merck
almost2y
The impact of RSV: a father’s story and call for prevention - Merck
~2y
Merck to Acquire Caraway Therapeutics, Inc. - Merck
~2y
Merck Announces Third-Quarter 2023 Financial Results - Merck
~2y
Daiichi Sankyo and Merck Announce Global Development and Commercialization Collaboration for Three Daiichi Sankyo DXd ADCs - Merck
~2y
Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC) - Merck
~2y
Merck's KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery - Merck
~2y
Merck Announces Second-Quarter 2023 Financial Results - Merck
>2y
Merck Announces First-Quarter 2023 Financial Results - Merck
>2y
Merck Provides Update on Phase 3 MOVe-AHEAD Trial Evaluating LAGEVRIO™ (molnupiravir) for Post-exposure Prophylaxis for Prevention of COVID-19 - Merck
almost3y
Merck Announces Second-Quarter 2022 Financial Results - Merck
>3y